Abstract:λ lncRNA‐modulated ceRNA networks may present a promising strategy for identifying candidate biomarkers in multiple types of human cancers λ VPS9D1‐AS1 and miR‐449a may serve as a potential therapeutic target in PCa. λ The findings in this study provide a better understanding of the ceRNA network involved in the prognosis of PCa and lay a solid foundation for improving PCa diagnosis and treatment. Despite advancements in cancer research, the prognostic implications of competing endogenous RNA (ceRNA) networks in prostate cancer (PCa) remain incompletely understood. This study aimed to elucidate the prognostic relevance of ceRNA networks in PCa, utilizing a comprehensive bioinformatics approach alongside experimental validation. After searching The Cancer Genome Atlas (TCGA) database, RNA sequencing (RNA‐Seq) data were extracted to identify differentially expressed RNAs (DERs) between 491 PCa samples and 51 normal prostate tissues, following which a comprehensive bioinformatics strategy was implemented to construct a ceRNA network. An optimal prognostic signature comprising these DERs was then established and validated using TCGA data. In addition, functional validation was performed through RNA pull‐down, dual‐luciferase reporter assays, quantitative real‐time PCR, and western blot analysis conducted in PC‐3 and DU145 cell lines, thereby complementing the bioinformatics analysis. A total of 613 DERs, comprising 103 long noncoding RNAs (lncRNAs), 60 microRNAs (miRNAs), and 450 messenger RNAs (mRNAs), were identified and utilized in constructing a ceRNA network, which encompassed 23 lncRNAs, 9 miRNAs, and 52 mRNAs. An optimal prognostic signature was established, including VPS9D1 antisense RNA 1 (VPS9D1‐AS1), miR‐449a, cyclin‐dependent kinase 5 regulatory subunit 1 (CDK5R1), targeting protein for Xklp2 (TPX2), solute carrier family 7 member 11 (SLC7A11), copine7 (CPNE7), and maternal embryonic leucine zipper kinase (MELK), yielding area under the curve (AUC) values exceeding 0.8 across training, validation, and entire datasets. Our experiments results revealed an interaction between lncRNA TRHDE antisense RNA 1 (TRHDE‐AS1) and miR‐449a and that miR‐449a could target the ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5) mRNA. Knockdown of miR‐449a significantly impeded cell proliferation, G1/S transition, migration and invasion, and promoted apoptosis in PC‐3 and DU145 cells. Furthermore, knockdown of miR‐449a notably downregulated protein expression of CDK4, cyclin D1, N‐cadherin and vimentin, while upregulating protein expression of cleaved caspase‐3 and E‐cadherin. This study contributes to a deeper understanding of the prognostic‐linked ceRNA network in PCa, providing fundamental insights that could improve diagnostic and therapeutic approaches for PCa management.

Unveiling four axes ADAMTS9-AS2|MEG3/hsa-miR-150/PRKCA|MMP14 within prostate cancer through establishment of the ceRNA network

The Transcriptomic Landscape of Prostate Cancer Development and Progression: an Integrative Analysis.

Identification and validation of the TRHDE‐AS1/hsa‐miR‐449a/ADAMTS5 axis as a novel prognostic biomarker in prostate cancer

Bioinformatics Analysis to Identify MEG3-hsa-miR-222-3p-NRG1/CLVS2 Axis as a Prognostic Biomarker in Prostate Cancer

Identification of the Key MicroRNAs and the miRNA-mRNA Regulatory Pathways in Prostate Cancer by Bioinformatics Methods

Identification of Pathologic and Prognostic Genes in Prostate Cancer Based on Database Mining

Four Novel Prognostic Genes Related to Prostate Cancer Identified Using Co-expression Structure Network Analysis

A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer

MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression

Multi-Omics Analysis of Primary Prostate Cancer Datasets Reveals Novel Biomarkers

Identification of novel biomarkers in prostate cancer diagnosis and prognosis

Integrated Analysis of a ceRNA (lncRNA-miRNA-mRNA) Regulatory Network for Prostate Cancer

Prediction of potential prognostic biomarkers in metastatic prostate cancer based on a circular RNA-mediated competing endogenous RNA regulatory network

Identification of Key MicroRNAs and Mechanisms in Prostate Cancer Evolution Based on Biomarker Prioritization Model and Carcinogenic Survey

Identification of Novel AR-Targeted MicroRNAs Mediating Androgen Signalling Through Critical Pathways to Regulate Cell Viability in Prostate Cancer

Identification of ARHGEF38, NETO2, GOLM1, and SAPCD2 Associated With Prostate Cancer Progression by Bioinformatic Analysis and Experimental Validation

Exploring the interaction between immune cells in the prostate cancer microenvironment combining weighted correlation gene network analysis and single-cell sequencing: An integrated bioinformatics analysis

A comparative mRNA- and miRNA transcriptomics reveals novel molecular signatures associated with metastatic prostate cancers

Identifying the key genes and microRNAs in prostate cancer bone metastasis by bioinformatics analysis

Identification of Candidate Hub Genes Correlated with the Pathogenesis, Diagnosis, and Prognosis of Prostate Cancer by Integrated Bioinformatics Analysis.

Crafting a Personalized Prognostic Model for Malignant Prostate Cancer Patients Using Risk Gene Signatures Discovered through TCGA-PRAD Mining, Machine Learning, and Single-Cell RNA-Sequencing